Skip to content
Bored Studies
RecruitingPhase 3

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Vega Therapeutics, Inc · NCT07115004

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 12–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
60
US sites recruiting
14
Study start
October 15, 2025
Record last updated
September 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Being studied: VGA039

Conditions: Von Willebrand Disease (VWD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • 12 to 75 years of age, inclusive
  • No clinically significant laboratory, ECG, or vital signs results
  • Documented diagnosis consistent with VWD of any type
  • Historical annualized bleeding rate (ABR; excluding menstrual bleeds and bleeds under the skin) of both untreated and treated bleeds ≥12 per year
  • Patients with VWD who are judged by the investigator to be suitable candidates for routine prophylaxis to reduce the frequency of bleeding episodes
  • Hemoglobin level ≥ 8 g/dL and platelet count ≥ 100 x 109/L at Screening

Key Exclusion Criteria

  • Use of routine prophylaxis of VWF-containing concentrates defined as at least 1 VWF-containing concentrate infusion to prevent or reduce bleeding per week during the previous 6 months prior to screening
  • Planning to initiate routine prophylaxis with VWF-containing concentrates or any other hemostatic treatment during the study
  • Patients with pro-thrombotic disorders or abnormal findings on laboratory thrombophilia evaluation performed at screening or previously documented
  • History of arterial or venous thrombosis, including superficial thrombophlebitis, or embolism
  • Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, or metabolic dysfunction
  • Baseline FVIII activity > lower limit of normal (LLN)

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trials- Vega Therapeutics · 650-466-8041 · trialtransparency@incyte.com
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von… (NCT07115004) | Bored Studies